Delivery Order SPE2DB20D2014-SPE2DB25FC62V
- Not listed
- The Defense Logistics Agency awarded a $2,416.05 firm fixed price delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of HUMIRA (CF) Pen 40 mg/0.4 mls, with completion scheduled for July 29, 2025. This non-competitive delivery order was placed against AmerisourceBergen's broader pharmaceutical supply contract vehicle and will be performed at the contractor's facility in Conshohocken, Pennsylvania. HUMIRA is a widely-used biologic medication for treating autoimmune...
- The Defense Logistics Agency awarded a $9,400.49 delivery order to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mL on July 29, 2025, with an ultimate completion date of July 30, 2025. This is a firm fixed-price, competitively awarded contract with no set-aside designation. The contractor will perform work at its corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,510.62 to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 80 mg/0.8 mL on August 1, 2025, with an ultimate completion date of August 4, 2025. This firm fixed-price delivery order was issued without a set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. HUMIRA is a widely-used pharmaceutical for treating various autoimmune conditions and is a critical medical supply required...
- The Defense Logistics Agency awarded a $3,828.03 delivery order to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mL pharmaceutical supplies on July 21, 2025, with an ultimate completion date of July 22, 2025. This firm fixed-price, non-set-aside contract represents a child delivery order under AmerisourceBergen's broader Indefinite Delivery Contract vehicle with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The supplies will be...
- The Defense Logistics Agency awarded a $19,774.30 firm fixed price delivery order to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mls on August 1, 2025, with an ultimate completion date of August 4, 2025. This non-competitive delivery order was issued under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), which carries a ceiling value of $999,999,999.00 through December 2026. The performance location is AmerisourceBergen's...
- The Defense Logistics Agency awarded a $9,183.92 delivery order to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mls on July 29, 2025, with a completion date of July 30, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and represents a single delivery under AmerisourceBergen's broader pharmaceutical supply agreement with DLA. The product will be delivered to AmerisourceBergen's distribution facility in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mls on July 28, 2025, with a ceiling value of $2,265.90 and an ultimate completion date of July 29, 2025. This is a firm fixed-price delivery order with no set-aside designation, meaning it was competitively awarded. The place of performance is listed as Conshohocken, Pennsylvania, which is AmerisourceBergen's headquarters location. This delivery order is a child contract issued...
- The Defense Logistics Agency awarded a $3,776.50 firm fixed-price delivery order to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mls, with an ultimate completion date of July 23, 2025. This competitive award, issued on July 22, 2025, carries no set-aside designation and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and running through December 2026. The performance...
- The Defense Logistics Agency awarded a delivery order valued at $34,594.70 to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mL on July 28, 2025, with a completion date of July 29, 2025. This non-competitive, firm fixed-price delivery order represents a fulfillment under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which carries a total value of $999,999,999.00 through December 2026. The product will be delivered to...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a $2,265.90 delivery order on July 18, 2025, for HUMIRA (CF) Pen 40 mg/0.4 mls, with completion scheduled for July 21, 2025. This competitive award, issued under firm fixed pricing with no set-aside designation, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) vehicle with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The pharmaceutical product...
- SPE2DB20D2014Indefinite Delivery Contract
- SPE2DB20D2014-SPE2DB25FC62VDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $1,510.60 to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mls on August 1, 2025, with an ultimate completion date of August 4, 2025. The contract employs firm fixed pricing with no set-aside designation, indicating it was competitively awarded. Performance will be executed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026, which serves as a comprehensive global pharmaceutical support vehicle for military healthcare programs. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, fulfills critical medical procurement needs for the Defense Health Agency, U.S. Coast Guard, and other federal healthcare systems through this contract vehicle. The IDC encompasses a broad spectrum of pharmaceutical products and medical supplies, including brand-name and generic medications, specialty drugs, vaccines, and medical devices across multiple therapeutic domains. This delivery order for HUMIRA, a TNF-inhibitor used in treating autoimmune conditions, exemplifies the company's role in supplying essential medications to support military healthcare operations worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.5k | 8/1/25 |